Undesirable side effects and high cost of the currently available synthetic α-glucosidase inhibitors drive the need to explore the natural sources for new inhibitors. Being a global lifestyle disorder that affects millions of people with
diverse genetic backgrounds, the search for alternate inhibitors is also desirable from the pharmacogenetics point of view. Crude extracts and purified compounds from M. charantia were reported to show anti-diabetic activities, which includes α-glucosidase inhibitory activity of the
available
diverse